Exploring how cGAS signaling affects brain cells in Alzheimer's disease
Official title: Investigating the role of cGAS signaling and microglial senscence in tauopathy
Funded at Weill Medical Coll of Cornell Univ · NIH-11164269 · Data updated 2026-11-12
This study is looking at how a specific signaling process in the brain might affect the progression of Alzheimer's disease, with the goal of finding new ways to help improve thinking and memory for people living with this condition.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 5, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $75,600 |
| NIH project number | 3K99AG078493-02S1 |
| Project ID | NIH-11164269 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related tauopathies.
✕Less likely to help
Patients with non-tau related forms of dementia or those without cognitive impairment may not benefit from this research.
What this research studies
This research investigates the role of cGAS signaling in the brains of patients with Alzheimer's disease, focusing on how this signaling pathway may contribute to the progression of tauopathy, a condition associated with Alzheimer's. The study uses advanced techniques such as behavioral assays and RNA sequencing to analyze the effects of cGAS on brain function and immune responses. By examining how cGAS interacts with microglial cells, which are crucial for brain health, the research aims to uncover potential therapeutic targets for improving cognitive function in Alzheimer's patients.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve memory and learning in patients with Alzheimer's disease.
How similar studies have gone: Previous research has shown that targeting immune pathways in neurodegenerative diseases can lead to significant improvements, suggesting that this approach may also be promising for Alzheimer's disease.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Amin, Sadaf — Weill Medical Coll of Cornell Univ
- Study coordinator: Amin, Sadaf
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.